Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
Your Article Summary
See Latest ArticlesRandomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer
Journal of Clinical Oncology, 09/11/09
Mok TSK et al. – Sequential administration of erlotinib following gemcitabine/platinum chemotherapy led to a significant improvement in PFS.
Methods- Previously untreated patients (n = 154) with stage IIIB or IV NSCLC and ECOG PS of 0 or 1 were randomly assigned to receive erlotinib (150 mg/d) or placebo on d 15-28 of a 4-w cycle that included gemcitabine (1,250 mg/m2 d 1 and 8) and either cisplatin (75 mg/m2 d 1) or carboplatin (5 x area under the serum concentration-time curve, d 1)
- The NPR at 8 weeks was 80.3% in the gemcitabine plus cisplatin or carboplatin (GC) -erlotinib arm (n = 76) and 76.9% in the GC-placebo arm (n = 78)
- At 16 w, the NPR was 64.5% for GC-erlotinib versus 53.8% for GC-placebo
- The response rate was 35.5% for GC-erlotinib versus 24.4% for GC-placebo
- PFS was significantly longer with GC-erlotinib than with GC-placebo (adjusted HR, 0.47; median, 29.4 v 23.4 w)
- There was no significant difference in OS
- The addition of erlotinib to chemotherapy was well tolerated, with no increase in hematologic toxicity, and no treatment-related interstitial lung disease
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
A Randomized Trial of Nebulized 3% Hypertonic Saline With Epinephrine in the Treatment of Acute Bronchiolitis in the Emergency Department
Archives of Pediatrics and Adolescent Medicine, 11/23/09
An Umbrella Review: Corticosteroid Therapy for Adults with Acute Asthma
American Journal of Medicine, 10/27/09
Clinical Studies of Combination Montelukast and Loratadine in Patients with Seasonal Allergic Rhinitis
Journal of Asthma, 11/11/09
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer
Journal of Clinical Oncology, 11/05/09
Tumor necrosis factor inhibitors and lung disease: A paradox of efficacy and risk
Seminars in Arthritis and Rheumatism, 11/20/09
Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial
Lung Cancer, 11/03/09
Sponsor
Article Search
Sponsor